Atara Biotherapeutics, Inc. (0HIY.L)
USD 5.42
(-4.9%)
USD 5.42
(-4.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 31.88 Million USD | 250.13% |
| 2022 | -21.23 Million USD | 73.64% |
| 2021 | -80.56 Million USD | 57.0% |
| 2020 | -187.36 Million USD | -211.33% |
| 2019 | -60.18 Million USD | -0.37% |
| 2018 | -59.96 Million USD | 23.83% |
| 2017 | -78.72 Million USD | -64.12% |
| 2016 | -47.96 Million USD | -102.0% |
| 2015 | -23.74 Million USD | -8.44% |
| 2014 | -21.89 Million USD | 57.58% |
| 2013 | -51.61 Million USD | -1126.88% |
| 2012 | -4.2 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 58.37 Million USD | -62.55% |
| 2024 Q1 | 57.11 Million USD | 79.11% |
| 2023 Q1 | 6.17 Million USD | 129.08% |
| 2023 Q3 | -2.98 Million USD | -115.88% |
| 2023 FY | 31.88 Million USD | 250.13% |
| 2023 Q4 | 31.88 Million USD | 1167.46% |
| 2023 Q2 | 18.81 Million USD | 204.52% |
| 2022 Q1 | -84.21 Million USD | -4.53% |
| 2022 Q3 | -4.04 Million USD | 39.57% |
| 2022 Q2 | -6.68 Million USD | 92.06% |
| 2022 FY | -21.23 Million USD | 73.64% |
| 2022 Q4 | -21.23 Million USD | -425.43% |
| 2021 Q2 | -111.67 Million USD | 19.39% |
| 2021 FY | -80.56 Million USD | 57.0% |
| 2021 Q1 | -138.52 Million USD | 26.06% |
| 2021 Q4 | -80.56 Million USD | 9.1% |
| 2021 Q3 | -88.63 Million USD | 20.63% |
| 2020 Q2 | -61.09 Million USD | -8.33% |
| 2020 Q4 | -187.36 Million USD | -278.58% |
| 2020 FY | -187.36 Million USD | -211.33% |
| 2020 Q3 | -49.49 Million USD | 18.99% |
| 2020 Q1 | -56.39 Million USD | 6.29% |
| 2019 Q4 | -60.18 Million USD | 24.68% |
| 2019 Q3 | -79.89 Million USD | -80.6% |
| 2019 Q2 | -44.24 Million USD | -6.01% |
| 2019 Q1 | -41.73 Million USD | 31.25% |
| 2019 FY | -60.18 Million USD | -0.37% |
| 2018 FY | -59.96 Million USD | 23.83% |
| 2018 Q4 | -60.69 Million USD | -8.92% |
| 2018 Q3 | -55.72 Million USD | 40.01% |
| 2018 Q2 | -92.9 Million USD | -15.85% |
| 2018 Q1 | -80.19 Million USD | -1.23% |
| 2017 FY | -78.72 Million USD | -64.12% |
| 2017 Q2 | -64.23 Million USD | -2.89% |
| 2017 Q3 | -60.49 Million USD | 5.83% |
| 2017 Q1 | -62.43 Million USD | -30.15% |
| 2017 Q4 | -79.22 Million USD | -30.96% |
| 2016 Q1 | -22.05 Million USD | 7.12% |
| 2016 FY | -47.96 Million USD | -102.0% |
| 2016 Q4 | -47.96 Million USD | -4.25% |
| 2016 Q3 | -46.01 Million USD | -74.58% |
| 2016 Q2 | -26.35 Million USD | -19.5% |
| 2015 Q3 | -54.46 Million USD | -107.96% |
| 2015 Q2 | -26.19 Million USD | 63.28% |
| 2015 Q1 | -71.32 Million USD | -225.75% |
| 2015 FY | -23.74 Million USD | -8.44% |
| 2015 Q4 | -23.74 Million USD | 56.4% |
| 2014 Q1 | -39.75 Million USD | 22.98% |
| 2014 Q3 | -25.7 Million USD | 19.12% |
| 2014 Q2 | -31.77 Million USD | 20.06% |
| 2014 FY | -21.89 Million USD | 57.58% |
| 2014 Q4 | -21.89 Million USD | 14.81% |
| 2013 Q4 | -51.61 Million USD | 0.0% |
| 2013 Q1 | 4.2 Million USD | 0.0% |
| 2013 FY | -51.61 Million USD | -1126.88% |
| 2012 FY | -4.2 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 130.971% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 202.14% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 83.902% |
| bluebird bio, Inc. | 108.57 Million USD | 70.632% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 453.649% |
| Imunon, Inc. | -4.69 Million USD | 778.509% |
| Editas Medicine, Inc. | -87.11 Million USD | 136.601% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.752% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 98.48% |
| Myriad Genetics, Inc. | 88.1 Million USD | 63.808% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 82.016% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 195.102% |
| Verastem, Inc. | -37.27 Million USD | 185.533% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.613% |
| Waters Corporation | 1.96 Billion USD | 98.374% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.881% |
| Biogen Inc. | 6.28 Billion USD | 99.493% |
| Nektar Therapeutics | 210.24 Million USD | 84.834% |
| Perrigo Company plc | 3.32 Billion USD | 99.04% |
| Dynavax Technologies Corporation | 106.63 Million USD | 70.099% |
| Illumina, Inc. | 1.21 Billion USD | 97.374% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -357.587% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 127.997% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 78.022% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -343.648% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 91.581% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 549.085% |
| Evolus, Inc. | 63.7 Million USD | 49.951% |
| Adicet Bio, Inc. | -142 Million USD | 122.453% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 186.635% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 217.657% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 93.049% |
| FibroGen, Inc. | 56.76 Million USD | 43.832% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 97.215% |
| OPKO Health, Inc. | 230.68 Million USD | 86.178% |
| Homology Medicines, Inc. | 18.43 Million USD | -72.94% |
| Geron Corporation | 14.76 Million USD | -116.008% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 97.989% |
| Exelixis, Inc. | -73.05 Million USD | 143.648% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 158.768% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 121.113% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 128.622% |
| Zoetis Inc. | 4.76 Billion USD | 99.33% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 115.957% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 416.602% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.333% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 318.81% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 96.976% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 96.707% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 123.549% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 97.691% |
| Blueprint Medicines Corporation | 702.83 Million USD | 95.463% |
| Insmed Incorporated | 721.62 Million USD | 95.581% |
| TG Therapeutics, Inc. | 17.86 Million USD | -78.507% |
| Incyte Corporation | -3.17 Billion USD | 101.004% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 95.836% |